Evaluating Prostate-Specific Antigen Screening for Young African American Men With Cancer.

ABSTRACT:

Background

Despite higher risks associated with prostate cancer, young African American men are poorly represented in prostate-specific antigen (PSA) trials, which limits proper evidence-based guidance. We evaluated the impact of PSA screening, alongside primary care provider utilization, on prostate cancer outcomes for these patients.

Methods

We identified African American men aged 40-55 years, diagnosed with prostate cancer between 2004 and 2017 within the Veterans Health Administration. Inverse probability of treatment-weighted propensity scores were used in multivariable models to assess PSA screening on PSA levels higher than 20, Gleason score of 8 or higher, and metastatic disease at diagnosis. Lead-time adjusted Fine-Gray regression evaluated PSA screening on prostate

SUBMITTER: Qiao EM 

PROVIDER: S-EPMC9002290 | biostudies-literature | 2022 Apr

REPOSITORIES: biostudies-literature